ClinicalTrials.gg
CompletedNCT03683719Updated Mar 12, 2025Results posted

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

A Phase 2 interventional study of Delgocitinib cream and Delgocitinib cream vehicle in Chronic Hand Eczema, sponsored by LEO Pharma. Completed at 28 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Eczema by LEO Pharma — 1 open to participants now, 1 under way, none of them phase 3. Eczema · LEO Pharma.

Enrollment
6th of 12
258 · median 178
Started
2018
with 1 other
Phase 2
3 of 13
none open now
Registered
5th of 13
by date

Among the 13 studies in Eczema by LEO Pharma, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2018, is one of 3 in phase 2, and was the 5th registered.

Eczema

506 studies on the registry are indexed under Eczema; 90 are open to participants now.

Browse Eczema studies →

Open to participants now

1 of the 13 studies in Eczema by LEO Pharma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Eczema by LEO Pharma, or all of them as a file.
02

Study summary

The purpose of this research trial was to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects chronic hand eczema. This was judged by a range of assessments that rate the severity and extent of chronic hand eczema and its symptoms, as well as general health status and quality of life.

03

Conditions studied

  • Chronic Hand Eczema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age 18 years or above.
  • Diagnosis of chronic hand eczema defined as hand eczema, which has persisted for more than 3 months or returned twice or more within the last 12 months.
  • Disease severity graded as mild to severe according to IGA (i.e., IGA ≥2).
  • Recent history (within 1 year before the screening visit) of inadequate response to topical treatment or topical corticosteroid treatment being medically inadvisable.
  • Diagnostic patch testing performed within 3 years prior to the screening visit.

Key Exclusion Criteria:

  • Concurrent skin diseases on the hands e.g tinnea manuum.
  • Active atopic dermatitis in regions other than the hands or psoriasis requiring medical treatment.
  • infection (e.g., impetiginised hand eczema) on the hands.
  • Systemic treatment with drugs, immunomodulating drugs, retinoids, or corticosteroids within 4 weeks prior to baseline.
  • Psoralen ultraviolet A (PUVA) or ultraviolet B (UVB) therapy on the hands within 4 weeks prior to baseline.
  • Receipt of 4 weeks prior to baseline.
  • Cutaneously applied treatment with immunomodulators (e.g., phosphodiesterase-4 (PDE-4) inhibitors, pimecrolimus, tacrolimus) or topical corticosteroids on the hands within 2 weeks prior to baseline.
  • Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 2 weeks prior to baseline.
  • Change in systemic antihistamine therapy within 2 weeks prior to baseline i.e., subjects must not start antihistamine treatment or change the current dosage regime within 2 weeks prior to baseline.
  • Other cutaneously applied therapy on the hands (except for the use of subject's own emollients) within 1 week prior to baseline.
  • Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 1 week prior to baseline.
  • Receipt of any marketed or biologic agents within 6 months or 5 half-lives prior to baseline or until cells count returns to normal, whichever is longer.
  • Clinically significant infection (systemic infection or serious skin infection requiring parenteral treatment) within 4 weeks prior to baseline.
  • Tuberculosis requiring treatment within 12 months prior to screening and/or subjects with a positive blood test for tuberculosis at screening.
  • History of any known primary immunodeficiency disorder including a positive (HIV) test at screening, or the subject taking antiretroviral medications.
  • Any disorder which is not stable and in the investigator's opinion could affect the safety of the subject, influence the findings of the trial, or impede the subject's ability to complete the trial.
  • Positive surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B core antibody (HBcAb), or virus antibody (anti-HCV) serology at screening. Subjects with positive HBsAb may be randomised provided they are hepatitis B vaccinated and have negative HBsAg and HBcAb.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
258 participants (actual)

Study arms

  • Experimental
    Delgocitinib cream 1 mg/g

    Delgocitinib cream applied twice daily for 16 weeks.

    Drug: Delgocitinib cream

  • Experimental
    Delgocitinib cream 3 mg/g

    Delgocitinib cream applied twice daily for 16 weeks.

    Drug: Delgocitinib cream

  • Experimental
    Delgocitinib cream 8 mg/g

    Delgocitinib cream applied twice daily for 16 weeks.

    Drug: Delgocitinib cream

  • Experimental
    Delgocitinib cream 20 mg/g

    Delgocitinib cream applied twice daily for 16 weeks.

    Drug: Delgocitinib cream

  • Placebo comparator
    Delgocitinib cream vehicle

    Delgocitinib cream vehicle applied twice daily for 16 weeks.

    Drug: Delgocitinib cream vehicle

Interventions

  • Cream for topical application.

    Also known as: LEO 124249 cream

  • DrugDelgocitinib cream vehicle

    The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.

    Also known as: LEO 124249 cream vehicle

06

What researchers measure

Primary outcomes

  1. Investigator's Global Assessment for Chronic Hand Eczema (IGA-CHE) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-step Improvement (IGA-CHE Treatment Success) From Baseline to Week 16.

    IGA-CHE is an instrument used in clinical trials to rate the severity of subject's global disease stage and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). The multiple comparison procedure - modelling (MCP-Mod) approach was used to guide dose selection. Cochran-Mantel-Haenszel analysis was used to determine the difference in response rates between the active delgocitinib cream doses and delgocitinib cream vehicle.

    Time frame: Week 0 to Week 16.

Secondary outcomes

  1. Change in Hand Eczema Severity Index (HECSI) From Baseline to Week 16.

    HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs of hand eczema and the extent of the lesions on each of 5 hand areas by use of standard scales. The total HECSI score is based on a 4-point severity scale ranging from 0 (none/absent) to 3 (severe) and a 5-point scale rating the affected area(s) ranging from 0 (0% affected area) to 4 (76% to 100% affected area). The lowest HECSI score is 0 and the highest possible is 360. A higher HECSI score is indicating more severe hand eczema. The multiple comparison procedure - modelling (MCP-Mod) approach was used to guide dose selection. A mixed model for repeated measurements (MMRM) analysis was used to determine the difference in the continuous endpoint between the active delgocitinib cream doses and delgocitinib cream vehicle.

    Time frame: Week 0 to Week 16.

  2. Time to IGA-CHE Treatment Success.

    Time to IGA-CHE treatment success response is defined as the time from baseline to first assessment of an IGA-CHE score of 0 (clear) or 1 (almost clear) with at least a 2-step improvement.

    Time frame: Week 0 to Week 16.

07

Results

Posted Apr 19, 2021

Participant flow

258 participants from 26 sites in 3 countries (U.S., Denmark, Germany) were randomised in this trial. The first participant was screened on 28-Nov-2018 and the last participant completed the trial on 20-Apr-2020.

Participant flow — Overall Study
MilestoneDelgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
Started5251525350
Completed4038444636
Not completed12138714
Withdrew: Lack of efficacy13404
Withdrew: Adverse event66013
Withdrew: Withdrawal by subject44355
Withdrew: Lost to follow-up10011
Withdrew: Other personal reasons00101

Outcome measures

PrimaryInvestigator's Global Assessment for Chronic Hand Eczema (IGA-CHE) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-step Improvement (IGA-CHE Treatment Success) From Baseline to Week 16.

IGA-CHE is an instrument used in clinical trials to rate the severity of subject's global disease stage and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). The multiple comparison procedure - modelling (MCP-Mod) approach was used to guide dose selection. Cochran-Mantel-Haenszel analysis was used to determine the difference in response rates between the active delgocitinib cream doses and delgocitinib cream vehicle.

Time frame:
Week 0 to Week 16.
Reported as:
Count of participants · Participants
Investigator's Global Assessment for Chronic Hand Eczema (IGA-CHE) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-step Improvement (IGA-CHE Treatment Success) From Baseline to Week 16.
ParticipantsDelgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
Investigator's Global Assessment for Chronic Hand Eczema (IGA-CHE) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-step Improvement (IGA-CHE Treatment Success) From Baseline to Week 16.11419204
Statistical analysis
  • Delgocitinib Cream 1 mg/g vs Delgocitinib Cream 3 mg/g vs Delgocitinib Cream 8 mg/g vs Delgocitinib Cream 20 mg/g vs Delgocitinib Cream Vehicle · Multiple contrast test · p = <0.001 (P-values were adjusted for multiple comparisons. Models with an adjusted p-value \<0.025 were statistically sign. different from a flat dose-response model. Model: IGA-CHE TS = Treatment + Region + Baseline IGA-CHE. Model selected: Emax model)
  • Delgocitinib Cream 1 mg/g vs Delgocitinib Cream Vehicle · Cochran-Mantel-Haenszel · p = >0.05 (The statistical test was not controlled for multiplicity. Data at visits following premature discont. of IMP or initiation of rescue medication before Week 16 were considered missing and imputed as non-responders (as were any other missing data).) · Risk difference (rd): 13.29 · 95% CI 0.34 to 26.24
  • Delgocitinib Cream 3 mg/g vs Delgocitinib Cream Vehicle · Cochran-Mantel-Haenszel · p = >0.05 (The statistical test was not controlled for multiplicity. Data at visits following premature discont. of IMP or initiation of rescue medication before Week 16 were considered missing and imputed as non-responders (as were any other missing data).) · Risk difference (rd): -0.03 · 95% CI -10.44 to 10.39
  • Delgocitinib Cream 8 mg/g vs Delgocitinib Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.001 (The statistical test was not controlled for multiplicity. Data at visits following premature discont. of IMP or initiation of rescue medication before Week 16 were considered missing and imputed as non-responders (as were any other missing data).) · Risk difference (rd): 28.22 · 95% CI 13.8 to 42.64
  • Delgocitinib Cream 20 mg/g vs Delgocitinib Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.001 (The statistical test was not controlled for multiplicity. Data at visits following premature discont. of IMP or initiation of rescue medication before Week 16 were considered missing and imputed as non-responders (as were any other missing data).) · Risk difference (rd): 29.61 · 95% CI 14.56 to 44.67
SecondaryChange in Hand Eczema Severity Index (HECSI) From Baseline to Week 16.

HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs of hand eczema and the extent of the lesions on each of 5 hand areas by use of standard scales. The total HECSI score is based on a 4-point severity scale ranging from 0 (none/absent) to 3 (severe) and a 5-point scale rating the affected area(s) ranging from 0 (0% affected area) to 4 (76% to 100% affected area). The lowest HECSI score is 0 and the highest possible is 360. A higher HECSI score is indicating more severe hand eczema. The multiple comparison procedure - modelling (MCP-Mod) approach was used to guide dose selection. A mixed model for repeated measurements (MMRM) analysis was used to determine the difference in the continuous endpoint between the active delgocitinib cream doses and delgocitinib cream vehicle.

Time frame:
Week 0 to Week 16.
Reported as:
Least squares mean · score on a scale
Change in Hand Eczema Severity Index (HECSI) From Baseline to Week 16.
score on a scaleDelgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
Change in Hand Eczema Severity Index (HECSI) From Baseline to Week 16.-39.81 ± 3.71-35.93 ± 3.77-46.69 ± 3.63-41.99 ± 3.59-26.40 ± 3.80
Statistical analysis
  • Delgocitinib Cream 1 mg/g vs Delgocitinib Cream 3 mg/g vs Delgocitinib Cream 8 mg/g vs Delgocitinib Cream 20 mg/g vs Delgocitinib Cream Vehicle · Multiple contrast test · p = <0.0001 (P-values were adjusted for multiple comparisons. Models with an adj. p-value \<0.025 were statistically sign. different from a flat dose-response model. Model: Change = Treatment + Baseline + Region + Baseline IGA-CHE. Model selected: Emax model)
  • Delgocitinib Cream 1 mg/g vs Delgocitinib Cream Vehicle · Mixed Models Analysis · p = <0.01 (The statistical test was not controlled for multiplicity. Data at visits following premature discont. of IMP or initiation of rescue med. before Week 16 were considered missing and imputed with MMRM predicted values (as were any other missing data).) · Mean difference (net): -13.41 · 95% CI -22.82 to -4.01
  • Delgocitinib Cream 3 mg/g vs Delgocitinib Cream Vehicle · Mixed Models Analysis · p = <0.05 (The statistical test was not controlled for multiplicity. Data at visits following premature discont. of IMP or initiation of rescue med. before Week 16 were considered missing and imputed with MMRM predicted values (as were any other missing data).) · Mean difference (net): -9.53 · 95% CI -19.04 to -0.02
  • Delgocitinib Cream 8 mg/g vs Delgocitinib Cream Vehicle · Mixed Models Analysis · p = <0.0001 (The statistical test was not controlled for multiplicity. Data at visits following premature discont. of IMP or initiation of rescue med. before Week 16 were considered missing and imputed with MMRM predicted values (as were any other missing data).) · Mean difference (net): -20.29 · 95% CI -29.56 to -11.02
  • Delgocitinib Cream 20 mg/g vs Delgocitinib Cream Vehicle · Mixed Models Analysis · p = <0.01 (The statistical test was not controlled for multiplicity. Data at visits following premature discont. of IMP or initiation of rescue med. before Week 16 were considered missing and imputed with MMRM predicted values (as were any other missing data).) · Mean difference (net): -15.59 · 95% CI -24.82 to -6.36
SecondaryTime to IGA-CHE Treatment Success.

Time to IGA-CHE treatment success response is defined as the time from baseline to first assessment of an IGA-CHE score of 0 (clear) or 1 (almost clear) with at least a 2-step improvement.

Time frame:
Week 0 to Week 16.
Reported as:
Number · days, median
Time to IGA-CHE Treatment Success.
days, medianDelgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
Time to IGA-CHE Treatment Success.NANA8298NA
Statistical analysis
  • Delgocitinib Cream 1 mg/g vs Delgocitinib Cream Vehicle · Log Rank · p = <0.05 (IGA-CHE TS was reached in less than 50% of participants, therefore the median time was not estimable. The statistical test was not controlled for multiplicity.)
  • Delgocitinib Cream 3 mg/g vs Delgocitinib Cream Vehicle · Log Rank · p = >0.1 (IGA-CHE TS was reached in less than 50% of participants, therefore the median time was not estimable. The statistical test was not controlled for multiplicity.)
  • Delgocitinib Cream 8 mg/g vs Delgocitinib Cream Vehicle · Log Rank · p = <0.0001 (The statistical test was not controlled for multiplicity.)
  • Delgocitinib Cream 20 mg/g vs Delgocitinib Cream Vehicle · Log Rank · p = <0.01 (The statistical test was not controlled for multiplicity.)

Adverse events

Collected over 18 weeks (from first application of IMP up until the last visit (safety follow-up visit)). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Delgocitinib Cream 1 mg/g0/52 (0%)0/52 (0%)20/52 (38.5%)
Delgocitinib Cream 3 mg/g0/51 (0%)2/51 (3.9%)25/51 (49%)
Delgocitinib Cream 8 mg/g0/52 (0%)1/52 (1.9%)25/52 (48.1%)
Delgocitinib Cream 20 mg/g0/53 (0%)0/53 (0%)26/53 (49.1%)
Delgocitinib Cream Vehicle0/50 (0%)0/50 (0%)24/50 (48%)
Most frequent serious events
Most frequent serious events
EventDelgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
Dizziness posturalNervous system disorders0/521/510/520/530/50
PemphigoidSkin and subcutaneous tissue disorders0/521/510/520/530/50
AnxietyPsychiatric disorders0/520/511/520/530/50
Most frequent other events
Most frequent other events
EventDelgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
NasopharyngitisInfections and infestations9/5215/5115/5214/5320/50
EczemaSkin and subcutaneous tissue disorders5/524/513/526/538/50
HeadacheNervous system disorders2/522/516/524/532/50
InfluenzaInfections and infestations1/521/510/524/530/50
Dermatitis atopicSkin and subcutaneous tissue disorders1/523/510/520/530/50
PruritusSkin and subcutaneous tissue disorders3/522/511/523/531/50
ToothacheGastrointestinal disorders3/521/510/520/530/50
Back painMusculoskeletal and connective tissue disorders1/520/512/523/531/50

Baseline characteristics

Age, Continuous
Age, Continuous(years)Delgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream VehicleTotal
Mean44.3 ± 13.646.1 ± 14.647.9 ± 12.943.9 ± 15.147.8 ± 16.246.0 ± 14.5
Sex: Female, Male
Sex: Female, Male(Participants)Delgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream VehicleTotal
Female3728323427158
Male1523201923100
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Delgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream VehicleTotal
Hispanic or Latino302139
Not Hispanic or Latino4951505247249
Unknown or Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Delgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream VehicleTotal
Race — White5151505250254
Race — Asian101103
Race — Other001001
Region of Enrollment
Region of Enrollment(participants)Delgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream VehicleTotal
United States4445421
Denmark12712111658
Germany3640363730179
Baseline IGA-CHE score
Baseline IGA-CHE score(Participants)Delgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream VehicleTotal
0 - Clear000000
1 - Almost clear000000
2 - Mild131311121261
3 - Moderate2929293127145
4 - Severe10912101152
Baseline HECSI score
Baseline HECSI score(units on a scale)Delgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream VehicleTotal
Mean59.0 ± 48.052.4 ± 35.949.5 ± 29.365.7 ± 58.352.7 ± 34.955.9 ± 42.8
08

Study locations

28 sites
  • Leo Pharma Investigational Site
    Tucson, Arizona 85724, United States
  • Leo Pharma Investigational Site
    Hialeah, Florida 33012, United States
  • Leo Pharma Investigational Site
    Portland, Oregon 97223, United States
  • Leo Pharma Investigational Site
    Portland, Oregon 97239-4501, United States
  • Leo Pharma Investigational Site
    Aarhus, 8200, Denmark
  • Leo Pharma Investigational Site
    Copenhagen, 2400, Denmark
  • Leo Pharma Investigational Site
    Hellerup, 2900, Denmark
  • LEO Pharma Investigational Site
    Herlev, 2730, Denmark
  • Leo Pharma Investigational Site
    Berlin, 10117, Germany
  • Leo Pharma Investigational Site
    Bochum, 44791, Germany
  • Leo Pharma Investigational Site
    Bremerhaven, 27574, Germany
  • Leo Pharma Investigational Site
    Dresden, 01307, Germany
  • Leo Pharma Investigational Site
    Düsseldorf, 40225, Germany
  • Leo Pharma Investigational Site
    Gera, 07548, Germany
  • Leo Pharma Investigational Site
    Göttingen, 37075, Germany
  • Leo Pharma Investigational Site
    Jena, 07743, Germany
  • Leo Pharma Investigational Site
    Kiel, 24105, Germany
  • Leo Pharma Investigational Site
    Kiel, 24148, Germany
  • Leo Pharma Investigational Site
    Langenau, 89129, Germany
  • Leo Pharma Investigational Site
    Lübeck, 23538, Germany
  • Leo Pharma Investigational Site
    Mahlow, 15831, Germany
  • Leo Pharma Investigational Site
    Mainz, 55101, Germany
  • Leo Pharma Investigational Site
    Memmingen, 87700, Germany
  • Leo Pharma Investigational Site
    München, 80337, Germany
  • Leo Pharma Investigational Site
    Selters, 56242, Germany
  • Leo Pharma Investigational Site
    Stuttgart, 70178, Germany
  • Leo Pharma Investigational Site
    Stuttgart, 70499, Germany
  • Leo Pharma Investigational Site
    Wuppertal, 42287, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Mar 2020, 15 months.

Results were first posted in Apr 2021, 1 year 1 month after primary completion.

Of 54 industry-sponsored phase 2 interventional studies under Eczema, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 16. This study's 15 months is above that.

Counting every sponsor, half of 70 studies reached it within 14 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2018
First posted
Sep 25, 2018
StartActual
Nov 28, 2018
Primary completionActual
Mar 6, 2020
CompletionActual
Apr 20, 2020
Results first posted
Apr 19, 2021
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03683719
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Sep 25, 2018
Start date
Nov 28, 2018
Primary completion
Mar 6, 2020
Completion
Apr 20, 2020
Results posted
Apr 19, 2021
Last update
Mar 12, 2025

Study contacts

Medical Expert
study director · LEO Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delgocitinib

Start the discussion